Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

• Status: Terminated
• Trial end date: 2019-02-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies.

Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation
• Treatments: Azacitidine; Gemcitabine; INCB057643; Paclitaxel; Rucaparib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:

• Part 1: solid tumors or lymphomas, or hematologic malignancies

• Part 2: histologically confirmed disease in specific tumor types

• Part 3: advanced solid tumor or hematologic malignancy

• Part 4: select advanced solid tumor or hematologic malignancy

• For Part 1 and 2, subjects must have progressed following at least 1 line of prior therapy and there is no further established therapy that is known to provide clinical benefit (including subjects who are intolerant to the established therapy)

• For Parts 3 and 4, subjects must have progressed following at least 1 line of prior therapy, and the treatment with the select SOC agent is relevant for the specific disease cohort.

• Life expectancy > 12 weeks, for MF subjects in Parts 3 and 4, life expectancy > 24 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status

• Parts 1 and 3: 0 or 1

• Parts 2 and 4: 0, 1, or 2

• Willingness to avoid pregnancy or fathering children

Exclusion Criteria:

• Inadequate bone marrow function per protocol-specified hemoglobin, platelet count, and absolute neutrophil count

• Inadequate organ function per protocol-specified total bilirubin, AST and ALT, creatinine clearance and alkaline phosphatase.

• Receipt of anticancer medications or investigational drugs within protocol-specified intervals

• Unless approved by the medical monitor, may not have received an allogeneic hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplant

• Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment

• Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy

• Radiotherapy within the 2 weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than 2 weeks before treatment initiation may be considered with medical monitor approval

• Currently active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment

• Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed

• History or presence of abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful

• Type 1 diabetes or uncontrolled Type 2 diabetes

• HbA1c of ≥ 8% (all subjects will have HbA1c test at screening)

• Any sign of clinically significant bleeding

• Coagulation panel within protocol-specified parameters